Fig. 2From: EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastomaLandscape, immune checkpoint expression, and cancer hallmarks scores among the subgroups of patients with cuproptosis. A SNV and inDel mutation profiles in subpopulations of patients with cuproptosis. B Copy number variation characteristics of patients with cuproptosis. C Differences in the frequency of copy number variation in subsets of patients with cuproptosis. D Differences in intratumoral heterogeneity scores among subgroups of patients with cuproptosis. E Differentially expressed immune checkpoint genes in the two patient subpopulations. F Hallmark expression scores of cancer were significantly different between the two patient subgroupsBack to article page